JP2019515909A5 - - Google Patents

Info

Publication number
JP2019515909A5
JP2019515909A5 JP2018554700A JP2018554700A JP2019515909A5 JP 2019515909 A5 JP2019515909 A5 JP 2019515909A5 JP 2018554700 A JP2018554700 A JP 2018554700A JP 2018554700 A JP2018554700 A JP 2018554700A JP 2019515909 A5 JP2019515909 A5 JP 2019515909A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
inhibitor
compound
ibrutinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018554700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515909A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028435 external-priority patent/WO2017184774A1/en
Publication of JP2019515909A publication Critical patent/JP2019515909A/ja
Priority to JP2022104680A priority Critical patent/JP2022121599A/ja
Publication of JP2019515909A5 publication Critical patent/JP2019515909A5/ja
Priority to JP2024095101A priority patent/JP2024111024A/ja
Pending legal-status Critical Current

Links

JP2018554700A 2016-04-19 2017-04-19 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 Pending JP2019515909A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022104680A JP2022121599A (ja) 2016-04-19 2022-06-29 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物
JP2024095101A JP2024111024A (ja) 2016-04-19 2024-06-12 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324733P 2016-04-19 2016-04-19
US62/324,733 2016-04-19
PCT/US2017/028435 WO2017184774A1 (en) 2016-04-19 2017-04-19 Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022104680A Division JP2022121599A (ja) 2016-04-19 2022-06-29 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物

Publications (2)

Publication Number Publication Date
JP2019515909A JP2019515909A (ja) 2019-06-13
JP2019515909A5 true JP2019515909A5 (https=) 2022-07-19

Family

ID=60117010

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554700A Pending JP2019515909A (ja) 2016-04-19 2017-04-19 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物
JP2022104680A Pending JP2022121599A (ja) 2016-04-19 2022-06-29 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物
JP2024095101A Pending JP2024111024A (ja) 2016-04-19 2024-06-12 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022104680A Pending JP2022121599A (ja) 2016-04-19 2022-06-29 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物
JP2024095101A Pending JP2024111024A (ja) 2016-04-19 2024-06-12 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物

Country Status (4)

Country Link
US (1) US11813261B2 (https=)
EP (1) EP3445364A4 (https=)
JP (3) JP2019515909A (https=)
WO (1) WO2017184774A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
US11298354B2 (en) * 2016-06-09 2022-04-12 Dana-Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors
JP7090611B2 (ja) 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド1(pd-l1)阻害剤とを含む医薬組み合わせ物及びその使用方法
US11433069B2 (en) 2017-12-01 2022-09-06 University of Modena and Reggio Emilia Methods of use and pharmaceutical combinations comprising histone deacetylase inhibitors and JAK1/2 inhibitors
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549633A (en) 1968-11-20 1970-12-22 Merck & Co Inc Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Il−6産生阻害剤
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
ES2294190T3 (es) 2001-11-01 2008-04-01 Janssen Pharmaceutica N.V. Derivados de amida como inhibidores de la glucogeno sintasa quinasa 3-beta.
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006528603A (ja) 2003-07-24 2006-12-21 ビーエーエスエフ アクチェンゲゼルシャフト 2−置換ピリミジン
WO2005028447A1 (en) 2003-09-22 2005-03-31 S*Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
CN101010298A (zh) 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
JP2009509923A (ja) 2005-08-26 2009-03-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬
WO2007052383A1 (ja) 2005-11-01 2007-05-10 Sumitomo Chemical Company, Limited 6,6−ジメチル−3−オキサビシクロ[3.1.0]ヘキサン−2−オンの製造方法
CA2641579A1 (en) 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US8304451B2 (en) 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US20100278782A1 (en) 2006-06-12 2010-11-04 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CN105481788A (zh) 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
JP2010519287A (ja) 2007-02-21 2010-06-03 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド α−ハロシクロプロピルカルボキシ化合物およびα−アルキルシクロプロピルカルボキシ化合物ならびにそれらの使用
KR101325374B1 (ko) 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
WO2009137462A2 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
EP2429987A4 (en) 2009-05-15 2012-10-03 Korea Res Inst Chem Tech AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
ES2736200T3 (es) 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
PH12012501492B1 (en) 2010-01-22 2020-01-24 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2571352A4 (en) 2010-05-21 2014-09-17 Sloan Kettering Inst Cancer SELECTIVE HDAC HEMMER
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
MX391121B (es) 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9096549B2 (en) 2013-02-01 2015-08-04 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US20140357512A1 (en) 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CA2926808A1 (en) 2013-10-11 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
WO2015084905A1 (en) 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストンデアセチラーゼ阻害剤による白血病の治療
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia

Similar Documents

Publication Publication Date Title
JP2019515909A5 (https=)
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
Gupta et al. Optimal management of fungal infections of the skin, hair, and nails
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
JP2015528471A5 (https=)
JP2021527092A5 (https=)
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
JP2016536286A5 (https=)
CN116712552A (zh) 用于治疗疱疹病毒诱导的病况的方法和组合物
JP2014526503A5 (https=)
JP2019517587A5 (https=)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
JP2014502641A5 (https=)
JP2023541430A5 (https=)
JP2023541432A5 (https=)
RU2019110150A (ru) Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции
JP2019517542A5 (https=)
JP2014516942A5 (https=)
JP2014505107A5 (https=)
JP2019536812A5 (https=)
JP2017533972A5 (https=)
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
JP2008535873A5 (https=)
WO2022007745A1 (zh) 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
JP2020536048A5 (https=)